Array
(
[Ovarian Cancer] => Array
(
[Austin] => https://www.survivornet.com/austin/
[Baltimore] => https://www.survivornet.com/baltimore/
[Charlotte] => https://www.survivornet.com/charlotte/
[Cleveland] => https://www.survivornet.com/cleveland/
[Columbus] => https://www.survivornet.com/columbus/
[Dallas / Ft. Worth] => https://www.survivornet.com/dallas-ftworth/
[Denver] => https://www.survivornet.com/denver/
[Detroit] => https://www.survivornet.com/detroit/
[Indianapolis] => https://www.survivornet.com/indianapolis-ovarian-cancer/
[Louisville] => https://www.survivornet.com/louisville/
[Memphis] => https://www.survivornet.com/memphis/
[Minneapolis] => https://www.survivornet.com/minneapolis/
[Nashville] => https://www.survivornet.com/nashville/
[Phoenix] => https://www.survivornet.com/phoenix/
[Portland] => https://www.survivornet.com/portland/
[Salt Lake City] => https://www.survivornet.com/salt-lake-city/
[San Antonio] => https://www.survivornet.com/san-antonio/
[San Diego] => https://www.survivornet.com/san-diego/
[San Francisco] => https://www.survivornet.com/san-francisco/
[San Jose] => https://www.survivornet.com/san-jose/
[Seattle] => https://www.survivornet.com/seattle/
) [Multiple Myeloma] => Array
(
[Ann Arbor] => https://www.survivornet.com/ann-arbor-michigan-multiple-myeloma-treatment/
[Miami] => https://www.survivornet.com/miami-florida-multiple-myeloma-treatment/
[Phoenix] => https://www.survivornet.com/phoenix-arizona-multiple-myeloma-treatment/
) [Glioma] => Array
(
[Midwest] => https://www.survivornet.com/midwest/
[Mountain States] => https://www.survivornet.com/glioma-mountain-states/
[Southeast] => https://www.survivornet.com/southeast/
) )
An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS) Summary The purpose of this study is to determine changes on overall gait as well as in multiple gait and balance parameters after withdrawal of dalfampridine-ER 10mg in MS subjects who are receiving the medication consistently for at least two weeks prior to screening.
View Eligibility Criteria Eligibility Criteria Inclusion Criteria: Diagnosis of multiple sclerosis Receiving Ampyra® consistently for at least 2 weeks prior to the screening visit No history of seizures except simple febrile seizures Exclusion Criteria: Sexually active woman of childbearing potential who is not surgically sterile, Subject who is pregnant or breastfeeding
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
OMRF Multiple Sclerosis Center of Excellence Oklahoma City Oklahoma, 73104, United States
How clear is this clinincal trial information?
Sign Up Sign up now for access to powerful tools, top experts, and customized information to help you fight cancer.
Personalized content tailored to your profile and disease type Access exclusive patient guides Breaking treatment information and expert perspectives and more... Sign Up Now Already have an account? Sign In
Sign Up Already have an account? Sign In
Sign In Don't have an account? Sign Up
Password reset is unavailable because your account was created using 'Sign Up with Google. To continue, please use the Google sign-in button below. Don't have an account? Sign Up